Rheumatoid Arthritis Therapy: Novel Therapies in the Pipeline

Session Type: ACR Concurrent Abstract Sessions
Tuesday, October 20, 2009: 2:30 PM-4:00 PM
Auditorium (Pennsylvania Convention Center)
Moderators: Jerry A. Molitor, MD, PhD, Univ of MN MMC108 and Johannes W. J. Bijlsma, MD, PhD, University Medical Center Utrecht
Papers:
2:30 PM
AIN457 Shows a Good Safety Profile and Clinical Benefit in Patients with Active Rheumatoid Arthritis (RA) Despite Methotrexate Therapy: 16-Weeks Results From a Randomized Proof-of-Concept Trial
Paul P. Tak, MD, PhD, Academic Medical Center/ University of Amsterdam; P. Durez, M, PhD, University of Louvain; JJ. Gomez-Reino, MD, PhD, University Clinical Hospital; B. Wittmer, M.D., Commonwealth Biomedical Research; V. Chindalore, MD, Pinnacle Research Group; F. Di Padova, Novartis Pharma AG; AM. Wright, Novartis Pharma AG; G. Bruin, Novartis Pharma AG; W. Hueber, M.D., Novartis Pharma AG
2:45 PM
Phase 2 Study of Safety and Efficacy of a Novel Anti-BAFF Monoclonal Antibody, in Patients with RA Treated with Methotrexate (MTX)
MC Genovese, M, M.D., Stanford U; E. Mociran, M, M.D., County Hospital; M. Biagini, M.D., County Hospital; S. Bojin, M.D., County Hospital; J. Sloan-Lancaster, PhD, Eli Lilly
3:00 PM
Safety and Efficacy After 24 Week (wk) Dosing of the Oral JAK Inhibitor CP-690,550 (CP) as Monotherapy in Patients (pts) with Active Rheumatoid Arthritis (RA)
R.M. Fleischmann, MD, Metroplex Clinical Research Center; M.C. Genovese, M, Stanford University; D. Gruben, Pfizer Inc; K.S. Kanik, MD, Pfizer Inc; G.V. Wallenstein, Pfizer Inc; B. Wilkinson, PhD, Pfizer Inc; S.H. Zwillich, MD, Pfizer Inc
3:15 PM
Safety and Efficacy After 24 Week (WK) Dosing of the Oral JAK Inhibitor CP-690,550 (CP) in Combination with Methotrexate (MTX) in Patients (PTS) with Active Rheumatoid Arthritis (RA)
J. Kremer, MD, Albany Medical College; S. Cohen, Metroplex Clinical Research Centre; B. Wilkinson, PhD, Pfizer Inc; D. Gruben, Pfizer Inc; G.V. Wallenstein, Pfizer Inc; K.S. Kanik, MD, Pfizer Inc; S.H. Zwillich, MD, Pfizer Inc
3:30 PM
Cam-3001; a Novel Human Monoclonal Antibody against GM-CSFR-á, in Subjects with Rheumatoid Arthritis (RA): Results of a Phi Study
Gerd-R. Burmester, M, Charite, University Medicine Berlin Free University and Humboldt University of Berlin; Frank Wagner, M, M.D., Charité Research Organisation GmbH, Berlin, Germany; Eugen Feist, M.D., Charite University Hospital; Matthew Sleeman, MedImmune Ltd; Fabio Magrini, M.D., Medimmune; Barbara White, M, M.D., Medimmune
3:45 PM
CH-1504, a Metabolically Inert Antifolate, Is An Effective and Well-Tolerated Treatment for Patients with Moderate to Severe Rheumatoid Arthritis
Edward C. Keystone, M.D., FRCP, (C), Professor of Medicine/University of Toronto; Lawrence A. Hewitt, PhD, Chelsea Therapeutics; Lee S. Simon, MD, Harvard Medical School; Valery Shirinsky, M.D., RAMS; Simon Pedder, PhD, Chelsea Therapeutics
See more of: ACR Concurrent Abstract Sessions

To see other sessions for this day, use the date buttons to the left.